Biotin USP Recalled for Lack of Stability Data and Controls
American Pharmaceutical Ingredients LLC is recalling Biotin USP for prescription compounding due to CGMP deviations, specifically a lack of stability data and controls to support expiration dates.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which is a reasonable probability of temporary or medically reversible adverse health consequences. The hazard is a CGMP deviation regarding stability data, which is a quality control issue rather than a direct contamination or mislabeling of a common allergen.
Plain-English summary
American Pharmaceutical Ingredients LLC is recalling Biotin USP (Vitamin H) for prescription compounding. The product is available in 500mg, 1g, 5g, and 25g packages and is packed by American Pharmaceutical Ingredients LLC in Waterford, Michigan. The recall involves a total of 7,255 g of the product.
The recall is due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the firm lacked stability data and controls to support the assigned retest or expiration dates in its container/closure system. This means the manufacturer did not have sufficient evidence to guarantee the product's stability over its labeled shelf life.
The affected lots are distributed nationwide within the USA. The specific lot numbers and expiration dates are: Lot 070815-2 (Exp. 04/24/2018) for 500mg, 1g, and 5g packages; Lot 110416-2 (Exp. 06/30/2019) for 5g packages; and Lot 110416-1 (Exp. 06/30/2019) and Lot 070815-1 (Exp. 04/24/2018) for 25g packages. Consumers and healthcare providers should stop using the product and contact their pharmacist or the recalling firm for instructions.
The recalled product
- Product
- Biotin USP (Vitamin H) for prescription compounding, packaged in a) 500mg (NDC 58597-8142-1); b) 1g (NDC 58597-8142-2); c) 5g (NDC 58597-8142-3); d ) 25g (NDC 58597-8142-4), Rx only, packed by American Pharmaceutical Ingredients, LLC 6650 Highland Road, Waterford, MI 48327
- Manufacturer
- American Pharmaceutical Ingredients LLC
- Category
- Drug — Pharmaceutical Ingredient
- Affected units
- 7,255
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot #: a) 070815-2
- Exp. 04/24/2018
- b) 070815-2
- c) 070815-2
- 110416-2
- Exp. 06/30/2019
- d) 110416-1
- 070815-1
- Exp. 04/24/2018.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 66 recalled by American Pharmaceutical Ingredients LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 66 products in this recall →Related recalls
Same manufacturer · American Pharmaceutical Ingredients LLC
See all →- ModerateAmerican Pharmaceutical Ingredients Recalls Sermorelin Acetate Powder Due to Stability Data
FDA (Drugs) · 2018-03-21
- ModerateOxytocin USP Powder Recalled Due to Insufficient Stability Data
FDA (Drugs) · 2018-03-21
- ModerateFDA Recalls Testosterone Cypionate Due to Missing Stability Data
FDA (Drugs) · 2018-02-28
- ModerateLevofloxacin Hemihydrate Recalled for Lack of Stability Data
FDA (Drugs) · 2018-02-28
- ModerateFDA Recalls Doxycycline Hyclate Due to Missing Stability Data
FDA (Drugs) · 2018-02-28
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19